

RANDOX

COMPREHENSIVE VIRAL RESPIRATORY INFECTION DETECTION

The Vivalytic multiplex Viral Respiratory Tract Infection (VRI) Array can identify SARS-CoV-2 (COVID-19) and differentiate it from other respiratory infections with similar symptoms, including influenza, RSV and all known coronaviruses.

The test only requires a single nasal swab from the patient and an easy four step process to be carried out by the user.

Detection Method: Randox Biochip Technology (End-Point PCR)

Result Time: 2.5 Hours

Sample Volume: 300µl Clinical Sample

Sample Type: Nasopharyngeal or Oropharyngeal Swab

VIRUS
SARS-CoV-2 (COVID-19)
Adenovirus A/B/C/D/E
Sarbecovirus (SARS, SARS Like, SARS-CoV-2)
Enterovirus A/B/C/D / Rhinovirus A/B/C
Coronavirus 229E/NL63
Influenza A
Coronavirus OC43/HKUI
Influenza B
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Respiratory Syncytial Virus A/B (RSV)



RANDOX

VIVALYTIC

Cartridge Based Testing Platform


The new SARS-CoV-2 lollipop pooling test will be conducted on Vivalytic, a point of care platform brought to the market by Randox Laboratories and Bosch. The Vivalytic system is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex infectious disease testing. Each easy to use cartridge contains all necessary reagents, is fully-sealed to minimise risk and can be conveniently stored at room temperature.

Vivalytic Key Features:

- Cartridge based platform
- Fully-automated
- Suitable for both non-laboratory & laboratory settings
- Small footprint device
- Rapid turnaround from sample entry to results

VIVALYTIC WORKFLOW

4 Easy Steps for Optimised Workflow



To find out more email:
marketing@randox.com